TrialSignal transduction and targeted therapy2023

Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial.

Huijie Bian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.